Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 26, 2026, 11:55 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 32 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Postoperative Ocular Pain Clear all
Terminated Phase 3 Interventional Results available

A Phase 3 Study Evaluating the Efficacy and Safety of OCS-01 Opthalmic Suspension Compared to Vehicle for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery

NCT06128369
View directory record Official record
Conditions
Inflammation Eye Pain, Postoperative Cataract
Interventions
OCS-01, Vehicle
Drug
Lead sponsor
Oculis
Industry
Eligibility
18 Years and older
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
24
States / cities
Glendale, California • Inglewood, California • Newport Beach, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Sep 26, 2026, 11:55 PM EDT
Completed Phase 2 Interventional Results available

OCS-01 in Treating Inflammation and Pain in Post-cataract Patients

NCT04130802
View directory record Official record
Conditions
Inflammation Corneal, Pain, Postoperative
Interventions
OCS-01 - Dexamethasone Cyclodextrin Nanoparticle Ophthalmic Suspension 1.5% mg/mL, Placebo
Drug
Lead sponsor
Oculis
Industry
Eligibility
18 Years and older
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
4
States / cities
Petaluma, California • Roseburg, Oregon • Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2025 · Synced Sep 26, 2026, 11:55 PM EDT
Completed Not applicable Interventional Results available

Postoperative Subtenons Anesthesia for Postoperative Pain in Pediatric Strabismus Surgery

NCT01812044
View directory record Official record
Conditions
Strabismus
Interventions
subtenons anesthetic - preservative-free bupivacaine 0.75%, topical anesthetic - 0.5 cc of lidocaine 3.5% ophthalmic gel, topical control - 0.5 cc of Hypromellose 0.3% gel, subtenons control - 0.5 cc of Normal Saline
Drug
Lead sponsor
Duke University
Other
Eligibility
1 Year to 7 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2013
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 25, 2016 · Synced Sep 26, 2026, 11:55 PM EDT
Completed Phase 2 Interventional Results available

Safety/Efficacy of Nepafenac Punctal Plug Delivery System Compared to Placebo to Control Ocular Pain/Inflammation After Cataract

NCT03496467
View directory record Official record
Conditions
Pain, Inflammation
Interventions
Nepafenac PPDS, Placebo PPDS
Combination Product
Lead sponsor
Mati Therapeutics Inc.
Industry
Eligibility
22 Years to 99 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
3
States / cities
Edgewood, Kentucky • Garden City, New York • Mt. Pleasant, South Carolina
Source: ClinicalTrials.gov public record
Updated Oct 11, 2021 · Synced Sep 26, 2026, 11:55 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Post-operative Pain Control After Photorefractive Keratectomy Comparing Acetaminophen/Codeine vs Acetaminophen/Oxycodone

NCT04399122
View directory record Official record
Conditions
Post-operative Pain Control
Interventions
acetaminophen/codeine vs acetaminophen/oxycodone
Drug
Lead sponsor
59th Medical Wing
Federal
Eligibility
21 Years and older
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 4, 2021 · Synced Sep 26, 2026, 11:55 PM EDT
Completed Phase 3 Interventional Results available

Safety, Efficacy and Pharmacokinetics of OMS302 in Subjects Undergoing Intraocular Lens Replacement With Phacoemulsification

NCT01579565
View directory record Official record
Conditions
Intraocular Lens Replacement
Interventions
OMS302, Placebo
Drug
Lead sponsor
Omeros Corporation
Industry
Eligibility
18 Years and older
Enrollment
416 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
13
States / cities
Chandler, Arizona • Los Angeles, California • Fort Myers, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2017 · Synced Sep 26, 2026, 11:55 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of KPI-121 in Subjects With Postsurgical Inflammation and Pain

NCT02793817
View directory record Official record
Conditions
Post Surgical Ocular Inflammation and Pain
Interventions
KPI-121 1% Ophthalmic Suspension dosed BID, Vehicle of KPI-121 Ophthalmic Suspension dosed BID
Drug
Lead sponsor
Kala Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
520 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
35
States / cities
Chandler, Arizona • Phoenix, Arizona • Artesia, California + 32 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2020 · Synced Sep 26, 2026, 11:55 PM EDT
Completed Phase 3 Interventional Results available

A Randomized Study in Children Ages Birth Through Three Years Undergoing Unilateral Cataract Extraction With or Without Lens Replacement

NCT02132312
View directory record Official record
Conditions
Unilateral Cataract Extraction, Congenital Cataract
Interventions
OMS302, Phenylephrine HCl
Drug
Lead sponsor
Omeros Corporation
Industry
Eligibility
1 Day to 47 Months
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
11
States / cities
Los Angeles, California • Atlanta, Georgia • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2021 · Synced Sep 26, 2026, 11:55 PM EDT
Completed Phase 2 Interventional Results available

Study of Efficacy and Safety of SAF312 Eye Drops in Subjects With Post-operative Corneal Induced Chronic Pain (CICP)

NCT04630158
View directory record Official record
Conditions
Chronic Ocular Pain
Interventions
SAF312 Placebo, SAF312
Other · Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
24
States / cities
Mission Hills, California • Newport Beach, California • Palo Alto, California + 19 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2024 · Synced Sep 26, 2026, 11:55 PM EDT
Terminated Phase 1 Interventional Results available

A Safety and Efficacy Study of a Dexamethasone Drug Delivery System for Postoperative Inflammation and Pain After Cataract Surgery

NCT01605942
View directory record Official record
Conditions
Cataract
Interventions
Dexamethasone Drug Delivery System, Placebo Drug Delivery System
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Jun 30, 2015 · Synced Sep 26, 2026, 11:55 PM EDT
Completed Phase 2 Interventional Results available

Study of SAF312 as an Eye Drop for Treatment of Eye Pain Following Photorefractive Keratectomy (PRK) Surgery

NCT02961062
View directory record Official record
Conditions
Postoperative Ocular Pain After PRK Surgery
Interventions
SAF312, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
4
States / cities
Chevy Chase, Maryland • Sioux Falls, South Dakota • Draper, Utah + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2021 · Synced Sep 26, 2026, 11:55 PM EDT
Completed Phase 2 Interventional Results available

RTA 408 Ophthalmic Suspension for the Prevention of Corneal Endothelial Cell Loss Following Cataract Surgery - GUARD

NCT02128113
View directory record Official record
Conditions
Corneal Endothelial Cell Loss, Ocular Pain, Ocular Inflammation, Cataract Surgery
Interventions
Vehicle Ophthalmic Solution, Omaveloxolone Ophthalmic Suspension 0.5%, Omaveloxolone Ophthalmic Suspension 1%
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 80 Years
Enrollment
307 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
15
States / cities
Laguna Hills, California • Lancaster, California • Cape Coral, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2025 · Synced Sep 26, 2026, 11:55 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Comparison of Postoperative Pain With Two Different Types of Local Anesthesia in Surgery for a Drooping Eyelid

NCT01350024
View directory record Official record
Conditions
Blepharoptosis
Interventions
Frontal nerve block with 2% lidocaine with 1:100,000 dilution of epinephrine, Subconjunctival injection of 2% lidocaine with 1:100,000 dilution with epinephrine
Procedure
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 100 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2016
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated May 29, 2017 · Synced Sep 26, 2026, 11:55 PM EDT
Completed Phase 4 Interventional Results available

Postoperative Pain Control Following Vitreoretinal Surgery

NCT01995045
View directory record Official record
Conditions
Retinal Detachment, Proliferative Vitreoretinopathy, Retinoschisis
Interventions
Triamcinolone, Bupivicaine Hydrochloride
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 89 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 20, 2017 · Synced Sep 26, 2026, 11:55 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of OMS302 in Subjects Undergoing Intraocular Lens Replacement With Phacoemulsification

NCT01454063
View directory record Official record
Conditions
Intraocular Lens Replacement
Interventions
OMS302, Placebo
Drug
Lead sponsor
Omeros Corporation
Industry
Eligibility
18 Years and older
Enrollment
405 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
16
States / cities
Chandler, Arizona • Glendale, Arizona • Los Angeles, California + 13 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2014 · Synced Sep 26, 2026, 11:55 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Topical Proparacaine Eye Drops to Improve the Experience of Patients Undergoing Intravitreal Injections

NCT02951351
View directory record Official record
Conditions
Age-related Macular Degeneration, Diabetic Macular Edema, Injection Site, Injection Site Infection, Pain, Postoperative
Interventions
Proparacaine, Conjunctival culture
Drug · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 11, 2023 · Synced Sep 26, 2026, 11:55 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Cannabinoid vs Opioid for Photorefractive Keratectomy Pain Control

NCT05477875
View directory record Official record
Conditions
Photorefractive Keratectomy, Myopia, Hyperopia
Interventions
oral cannabinoid, oral codeine/acetaminophen
Drug · Combination Product
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 65 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Aug 6, 2025 · Synced Sep 26, 2026, 11:55 PM EDT
Completed Phase 3 Interventional Results available

A Phase 3 Study Evaluating the Efficacy and Safety of OCS-01 Eyedrops Compared to Vehicle for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery

NCT05147233
View directory record Official record
Conditions
Inflammation Eye Pain, Postoperative Cataract
Interventions
OCS-01, Vehicle
Drug
Lead sponsor
Oculis
Industry
Eligibility
18 Years and older
Enrollment
241 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
25
States / cities
Chandler, Arizona • Phoenix, Arizona • Fayetteville, Arkansas + 21 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2025 · Synced Sep 26, 2026, 11:55 PM EDT
Completed Phase 4 Interventional

Omidria and Dexycu, or Omidria and Dextenza Compared to Topical Prednisolone Acetate 1% Following Cataract Surgery

NCT04316936
View directory record Official record
Conditions
Cataract Surgery
Interventions
Omidria, Dextenza (dexamethasone ophthalmic insert) 0.4mg, Dexycu, 9% Intraocular Suspension, Prednisolone Acetate 1%
Drug
Lead sponsor
Silverstein Eye Centers
Other
Eligibility
Not listed
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 14, 2023 · Synced Sep 26, 2026, 11:55 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Dextenza for Post-operative Treatment of Pterygium

NCT04351737
View directory record Official record
Conditions
Pterygium of Both Eyes
Interventions
Intracanalicular Dexamethasone, (0.4 mg) Insert, Prednisolone Acetate
Drug
Lead sponsor
Brandon Eye Associates, PA
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Brandon, Florida
Source: ClinicalTrials.gov public record
Updated May 24, 2025 · Synced Sep 26, 2026, 11:55 PM EDT
Completed Phase 2 Interventional

Iontophoretic Delivery of EGP-437 in Patients Who Have Undergone Cataract Surgery

NCT03180255
View directory record Official record
Conditions
Cataract, Anterior Chamber Inflammation, Pain, Postoperative
Interventions
Dexamethasone phosphate, Placebo
Combination Product · Other
Lead sponsor
Eyegate Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated May 20, 2018 · Synced Sep 26, 2026, 11:55 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

fMRI and IVCM Cornea Microscopy of CXL in Keratoconus

NCT04439552
View directory record Official record
Conditions
Pain, Postoperative, Pain, Chronic, Pain, Acute, Surgical Injury, Surgical Wound, Cornea Injury, Cornea, Keratoconus
Interventions
Not listed
Lead sponsor
Boston Children's Hospital
Other
Eligibility
8 Years to 35 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 18, 2025 · Synced Sep 26, 2026, 11:55 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of KPI-121 in Subjects With Postsurgical Inflammation

NCT02163824
View directory record Official record
Conditions
Ocular Infections, Irritations and Inflammations
Interventions
KPI-121 0.25%, KPI-121 1.0%, Vehicle of KPI-121 0.25%, Vehicle of KPI-121 1.0%
Drug
Lead sponsor
Kala Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
380 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
23
States / cities
Artesia, California • Mission Hills, California • Rancho Cordova, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2021 · Synced Sep 26, 2026, 11:55 PM EDT
Suspended Phase 2 Interventional

Pain After Strabismus Surgery

NCT06689943
View directory record Official record
Conditions
Strabismus
Interventions
Tylenol
Drug
Lead sponsor
Ann & Robert H Lurie Children's Hospital of Chicago
Other
Eligibility
4 Years to 12 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Sep 26, 2026, 11:55 PM EDT